Efficacy of adjunctive periodontal interventions in non-surgical periodontal therapy for Stage III/IV Grade C periodontitis: A systematic review and network meta-analysis

This study evaluates the effectiveness of adjunctive therapies combined with non-surgical periodontal treatment for Stage III/IV Grade C periodontitis, focusing on pocket depth (PD) reduction, clinical attachment level (CAL) gain, and adverse events. A systematic review and network meta-analysis wer...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Shih-Ying Lin, Hung-Ying Lin, Jui-Sheng Sun, Jenny Zwei-Chieng Chang
Natura: Articolo
Lingua:inglese
Pubblicazione: Elsevier 2025-12-01
Serie:Japanese Dental Science Review
Soggetti:
Accesso online:http://www.sciencedirect.com/science/article/pii/S1882761625000134
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!
Descrizione
Riassunto:This study evaluates the effectiveness of adjunctive therapies combined with non-surgical periodontal treatment for Stage III/IV Grade C periodontitis, focusing on pocket depth (PD) reduction, clinical attachment level (CAL) gain, and adverse events. A systematic review and network meta-analysis were conducted, including randomized controlled trials up to September 2024. Inconsistencies and publication bias were detected, prompting sensitivity analyses and effectiveness rankings of adjunctive therapies. Data from 50 studies were included, with 45 entered into network meta-analysis, covering 24 interventions and 1431 patients. Compared to scaling and root planing (SRP) alone, adjunctive systemic lincosamides with nitroimidazole (Mac/Linc+Nitro-S) demonstrated the greatest PD reduction, followed by local statins (Statins-L) in the short term (≤3 months). Statins-L also provided the highest CAL gain. In the medium term (4–6 months), Statins-L remained the most effective, followed by bisphosphonates. For long-term (>6 months) follow-up, where fewer treatment approaches were available, Nitro-S achieved the most significant PD reduction and CAL gain, followed by Mac/Linc-S. Adverse effects were mild and self-limiting. Despite promising findings, inconsistencies in CAL outcomes and potential publication bias highlight the need for further research to confirm long-term safety and efficacy.
ISSN:1882-7616